OCEA Stock Chart & Stats
$0.01
-$0.06(-8.34%)
At close: 4:00 PM EST
$0.01
-$0.06(-8.34%)
Day’s Range― - ―
52-Week Range<$0.01 - $2.03
Previous CloseN/A
Volume122.53K
Average Volume (3M)65.25M
Market Cap
$23.24K
Enterprise Value$8.69M
Total Cash (Recent Filing)$777.00K
Total Debt (Recent Filing)$9.35M
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding232,365,140
10 Day Avg. Volume10,587,623
30 Day Avg. Volume65,252,820
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-0.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.64
Enterprise Value/Market Cap374.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Ocean Biomedical News
OCEA FAQ
What was Ocean Biomedical’s price range in the past 12 months?
Ocean Biomedical lowest stock price was <$0.01 and its highest was $2.03 in the past 12 months.
What is Ocean Biomedical’s market cap?
Ocean Biomedical’s market cap is $23.24K.
When is Ocean Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ocean Biomedical’s earnings last quarter?
Currently, no data Available
Is Ocean Biomedical overvalued?
According to Wall Street analysts Ocean Biomedical’s price is currently Overvalued.
Does Ocean Biomedical pay dividends?
Ocean Biomedical does not currently pay dividends.
What is Ocean Biomedical’s EPS estimate?
Ocean Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocean Biomedical have?
Ocean Biomedical has 232,365,140 shares outstanding.
What happened to Ocean Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocean Biomedical?
Currently, no hedge funds are holding shares in OCEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocean Biomedical
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---